We've known that Intercept Pharmaceuticals Inc.'s FLINT trial evaluating obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) was positive since the data safety monitoring stopped the trial early for positive efficacy in January. (See BioWorld Today, Jan. 10, 2014.)
According to calculations by Morrison & Foerster LLP's Biometer, the average up-front payment for biotech deals in the third quarter came in at $43.7 million, up from $30.4 million in the year-ago quarter.
A report from Tufts Center for the Study of Drug Development (CSDD) highlights the evolving relationships between contract research organizations (CROs) and clinical trial sponsors through the adoption of strategic partnerships.
LA JOLLA, Calif. – Gene therapy has come a long way from using retroviral vectors to insert gamma-chain transgenes into cells of children with severe combined immunodeficiency in the early 1990s, an act that increased the risk of developing leukemia.
LA JOLLA, Calif. – Stem cells offer promising new treatments, but panelists at a session during the annual Stem Cell Meeting on the Mesa warned the audience that the treatments' unique features pose challenges to gaining reimbursement.
The third quarter typically sees fewer venture capital investments than the second quarter – not surprising since it covers prime vacation time. While I'm sure more than one deal has been consummated from the beach, VCs deserve their downtime, too.
Rather than riding off into the sunset after successfully developing a biotech company and getting it sold to a big pharma, many CEOs start anew, trying to show that lightning can strike twice (or more).
